Data from clinical trials indicate that miR-106b is down-regulated in sporadic AD patients and SH-SY5Y cells (31), and can inhibit Aβ42-induced Tau phosphorylation at the site of Tyr18. This evidence concerns the gene MAPT and Alzheimer disease.